Identification of Epstein–Barr Virus-induced Polypeptides in P3HR-1 Cells by Protein Immunoblot Free

Abstract

SUMMARY

The protein immunoblot technique was used to identify Epstein-Barr virus-specific antigens present in sodium butyrate-induced P3HR-1 cells. Using sera from patients with either nasopharyngeal carcinoma or arthritis, 16 polypeptides were detected ranging in molecular weight from 22K to 140K. Each of the anti-EA-, anti-VCA-positive sera were found to contain antibodies to different subsets of the antigens. A 72K protein was identified which was consistent with the nuclear antigen (EBNA), and culturing cells in the presence of disodium phosphonoacetate allowed identification of 140K and 22K antigens as late viral products. Treatment of cells with sodium butyrate revealed that expression of some antigens increased in parallel with the time of incubation of the cells in butyrate while other antigens either appeared early and then decreased in intensity or were only present after a number of days of butyrate treatment. One of the antigens which decreased with the time cells were treated with butyrate was EBNA.

Keyword(s): EBV , polypeptides and protein immunoblot
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-66-5-1113
1985-05-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/66/5/JV0660051113.html?itemId=/content/journal/jgv/10.1099/0022-1317-66-5-1113&mimeType=html&fmt=ahah

References

  1. Baer R., Bankier A. T., Biggin M. D., Deininger P. L., Farrell P. J., Gibson T. J., Hatfull G., Hudson G. S., Satchwell S. C., Seguin C., Tuffnell P. S., Barrell B. G. 1984; DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature, London 310:207–211
    [Google Scholar]
  2. Bayliss G. J., Wolf H. 1981; The regulated expression of Epstein-Barr virus. III. Proteins specified by EBV during the lytic cycle. Journal of General Virology 56:105–118
    [Google Scholar]
  3. Bayliss G. J., Deby G., Wolf H. 1983; An immunoprecipitation blocking assay for the analysis of EBV-induced antigens. Journal of Virological Methods 7:229–239
    [Google Scholar]
  4. Boguszaková L., Hirsch L. B., řicháček B., Vonka V. 1983; Relationship between Epstein-Barr virus nuclear antigen and DNA genome number in superinfected and induced lymphoblastoid cell lines. Journal of General Virology 64:887–894
    [Google Scholar]
  5. Burnette W. N. 1981; ‘‘Western Blotting”: electrophoretic transfer of proteins from SDS–polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated Protein A. Analytical Biochemistry 112:195–203
    [Google Scholar]
  6. Cohen L. K., Speck S. H., Roberts B. E., Strominger J. L. 1984; Identification and mapping of polypeptides encoded by the P3HR-1 strain of Epstein-Barr virus. Proceedings of the National Academy of Sciences, U. S. A 81:4183–4187
    [Google Scholar]
  7. Edson C. M., Cohen L. K., Henle W., Strominger J. L. 1983; An unusually high-titer human anti-Epstein-Barr virus (EBV) serum and its use in the study of EBV-specific proteins synthesised in vitro and in vivo . Journal of Immunology 130:919–924
    [Google Scholar]
  8. Epstein A. L. 1984; Immunobiochemical characterisation with monoclonal antibodies of Epstein–Barr virus-associated early antigens in chemically induced cells. Journal of Virology 50:372–379
    [Google Scholar]
  9. Gergely L., Klein G., Ernberg I. 1971; Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology 45:10–21
    [Google Scholar]
  10. Hampar B., Derge J. G., Martos L. M., Tagamets M. A., Chang S. Y., Chakrabarty M. 1973; Identification of a critical period during the S-phase for activation of the Epstein–Barr virus by 5-iododeoxyuridine. Nature, London 224:214–217
    [Google Scholar]
  11. Henle G., Henle W. 1966; Immunofluorescence in cells derived from Burkitt’s lymphoma. Journal of Bacteriology 91:1248–1256
    [Google Scholar]
  12. Henle G., Henle W., Klein G. 1971; Demonstration of two distinct components in the early antigen complex of Epstein–Barr virus-infected cells. International Journal of Cancer 8:272–278
    [Google Scholar]
  13. Kallin B., Luka J., Klein G. 1979; Immunochemical characterisation of Epstein–Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. Journal of Virology 32:710–726
    [Google Scholar]
  14. Kawanashi M., Sugawara K., Ito Y. 1981; Epstein-Barr virus-induced polypeptides: a comparative study with superinfected Raji, IUdR-treated and n-butyrate-treated P3HR-1 cells. Virology 109:72–81
    [Google Scholar]
  15. Kishishita M., Luka J., Vromin B., Puduslo J. F., Pearson G. R. 1984; Production of monoclonal antibody to a late intracellular Epstein–Barr virus-induced antigen. Virology 133:363–375
    [Google Scholar]
  16. Klein G., Dombos L. 1973; Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genomes. International Journal of Cancer 11:327–337
    [Google Scholar]
  17. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, London 227:680–685
    [Google Scholar]
  18. Luka J., Kallin B., Klein G. 1979; Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228–231
    [Google Scholar]
  19. Moss D. J., Chan S. H., Burrows S. R., Chew T. S., Kane R. G., Staples J. A., Kunaratnam N. 1983a; Epstein–Barr virus specific T-cell response in nasopharyngeal carcinoma patients. International Journal of Cancer 32:301–305
    [Google Scholar]
  20. Moss D. J., Klestov A., Burrows S., Kane R. G. 1983b; A comparison of Epstein-Barr virus-specific T-cell immunity in rheumatoid arthritis and osteoarthritis patients. Australian Journal of Experimental Biology and Medical Science 61:509–516
    [Google Scholar]
  21. Mueller-Lantzsch N., Yamamoto N., Zur Hausen H. 1979; Analysis of early and late Epstein-Barr virus-associated polypeptides by immunoprecipitation. Virology 97:378–387
    [Google Scholar]
  22. Pearson G. R. 1980; Epstein–Barr virus: immunology. In Viral Oncology pp 739–767 Edited by Klein G. New York: Raven Press;
    [Google Scholar]
  23. Pearson G. R., Vroman B., Chase B., Sculley T., Hummel M., Kieff E. 1983; Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. Journal of Virology 47:193–201
    [Google Scholar]
  24. Qualtiere L. F., Chase R., Vroman B., Pearson G. R. 1982; Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein. Proceedings of the National Academy of Sciences, U. S. A 79:616–620
    [Google Scholar]
  25. Reedman T. B. M., Klein G. 1973; Cellular localisation of an Epstein–Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. International Journal of Cancer 2:499–520
    [Google Scholar]
  26. Roubal J., Kallin B., Luka J., Klein G. 1981; Early DNA-binding polypeptides of Epstein-Barr virus. Virology 113:285–292
    [Google Scholar]
  27. Sculley T. B., Spelsberg T. C., Pearson G. R. 1984a; Characterisation of Epstein-Barr virus nuclear antigen(s) in different cell lines by radioimmunoelectrophoresis. Intervirology 22:191–200
    [Google Scholar]
  28. Sculley T. B., Walker P. J., Moss D. I., Pope J. H. 1984b; Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis. Journal of Virology 52:88–93
    [Google Scholar]
  29. Strnad B. C., Schuster T. C., Hopkins R. F. Ill, Neubauer R. H., Rabin H. 1981; Identification of an Epstein-Barr virus nuclear antigen by fluoroimmunoelectrophoresis and radioimmunoelectrophoresis. Journal of Virology 38:996–1004
    [Google Scholar]
  30. Sugawara K., Kawanashi M., Ito Y. 1982; Epstein-Barr virus-related DNA-binding proteins induced by n-butyrate in P3HR-1 cells. Virology 116:354–358
    [Google Scholar]
  31. Takeda K., Fujiwara S., Yano S., Osato T. 1983; Monoclonal antibody specific for capsid antigen of Epstein–Barr virus. Medical Microbiology and Immunology 171:225–231
    [Google Scholar]
  32. Thorley-Lawson D. A., Edson C. M., Geilinger K. 1982; Epstein–Barr virus antigens – a challenge to modern biochemistry. Advances in Cancer Research 36:295–348
    [Google Scholar]
  33. Zur Hausen H., O’Neill F. J., Freese U. K. 1978; Persisting oncogenic herpesvirus induced by the tumour promoter TPA. Nature, London 272:373–375
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-66-5-1113
Loading
/content/journal/jgv/10.1099/0022-1317-66-5-1113
Loading

Data & Media loading...

Most cited Most Cited RSS feed